Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angeles Alvarez Secord

Showing results (141-150 of 239) with videos related to

Pageof 24
Sort By:
Gynecologic Oncology|April 30, 2013
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapyRobert M Wenham, James Lapolla, Hui-Yi Lin, et al.
Gynecologic Oncology|August 12, 2015
Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinomaSharareh Siamakpour-Reihani, Kouros Owzar, Chen Jiang, et al.
Cancer|August 28, 2019
Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancerLaura J Havrilesky, Jui-Chen Yang, Paula S Lee, et al.
Gynecologic Oncology|May 11, 2020
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisisBhavana Pothuri, Angeles Alvarez Secord, Deborah K Armstrong, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 26, 2020
Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practicesCatherine H Watson, Lindsay Soo, Brittany A Davidson, et al.
Gynecologic Oncology|April 18, 2026
Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancerAya Bashi, Katherine N Penvose, Jason D Wright, et al.
Gynecologic Oncology|November 26, 2013
Metformin is associated with improved survival in endometrial cancerEmily M Ko, Paige Walter, Amanda Jackson, et al.
Gynecologic Oncology|April 1, 2014
The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significanceEmily M Ko, Paige Walter, Leslie Clark, et al.
Gynecologic Oncology|September 5, 2018
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group studyWilliam P Tew, Michael W Sill, Joan L Walker, et al.
Gynecologic Oncology|September 28, 2011
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trialRobin Pokrzywinski, Angeles Alvarez Secord, Laura J Havrilesky, et al.
Pageof 24

Showing results (141-150 of 239) with videos related to

Sort By:
Pageof 24
Gynecologic Oncology|April 30, 2013
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapyRobert M Wenham, James Lapolla, Hui-Yi Lin, et al.
Gynecologic Oncology|August 12, 2015
Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinomaSharareh Siamakpour-Reihani, Kouros Owzar, Chen Jiang, et al.
Cancer|August 28, 2019
Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancerLaura J Havrilesky, Jui-Chen Yang, Paula S Lee, et al.
Gynecologic Oncology|May 11, 2020
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisisBhavana Pothuri, Angeles Alvarez Secord, Deborah K Armstrong, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 26, 2020
Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practicesCatherine H Watson, Lindsay Soo, Brittany A Davidson, et al.
Gynecologic Oncology|April 18, 2026
Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancerAya Bashi, Katherine N Penvose, Jason D Wright, et al.
Gynecologic Oncology|November 26, 2013
Metformin is associated with improved survival in endometrial cancerEmily M Ko, Paige Walter, Amanda Jackson, et al.
Gynecologic Oncology|April 1, 2014
The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significanceEmily M Ko, Paige Walter, Leslie Clark, et al.
Gynecologic Oncology|September 5, 2018
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group studyWilliam P Tew, Michael W Sill, Joan L Walker, et al.
Gynecologic Oncology|September 28, 2011
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trialRobin Pokrzywinski, Angeles Alvarez Secord, Laura J Havrilesky, et al.
Pageof 24